A mobile health intervention in HIV primary care: supporting patients at risk for ART non-adherence.


Journal

HIV research & clinical practice
ISSN: 2578-7470
Titre abrégé: HIV Res Clin Pract
Pays: England
ID NLM: 101738312

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 29 12 2020
medline: 20 8 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Mobile health (mHealth) interventions that are integrated in HIV clinical settings to facilitate ongoing patient-provider communication between primary care visits are garnering evidence for their potential in improving HIV outcomes. Rango is an mHealth intervention to support engagement in HIV care and treatment adherence. This study used a single-arm prospective design with baseline and 6-month assessments for pre-post comparisons, as well as a matched patient sample for between-group comparisons to test Rango's preliminary efficacy in increasing viral suppression. The Rango sample (n = 406) was predominantly 50 years of age or older (63%; M = 50.67; SD = 10.97, 23-82), Black/African-American (44%) or Hispanic/Latinx (38%), and male (59%). At baseline, 18% reported missing at least one dose of ART in the prior three days and chart reviews of recent VL showed that nearly 82% of participants were virally suppressed. Overall 95% of the patients enrolled in Rango returned for a medical follow-up visit. Of the 65 unsuppressed patients at baseline who returned for a medical visit, 38 (59%) achieved viral suppression and only 5% of the suppressed group at baseline had an increase in viral load at 6 months despite being at risk for ART non-adherence. While viral suppression was similar between Rango participants and patients receiving treatment as usual over the same time period, it is unknown whether those patients were similarly at risk for non-adherence. Our findings support efforts to formally test this innovative approach in addressing ART non-adherence and viral suppression particularly to reach HIV treatment goals.

Identifiants

pubmed: 33369547
doi: 10.1080/25787489.2020.1862972
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-150

Auteurs

Ana Ventuneac (A)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Emma Kaplan-Lewis (E)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Jessamine Buck (J)

VillageCare, New York, NY, USA.

Randi Roy (R)

VillageCare, New York, NY, USA.

Caitlin E Aberg (CE)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Bianca A Duah (BA)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Emily Forcht (E)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Michelle Cespedes (M)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Judith A Aberg (JA)

Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH